Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

总部位于新泽西州泽西市的制药公司Organon & Co.报告了其高管团队的重大变动。自2025年1月15日起，Susanne Fiedler已立即卸任首席商务官一职。虽然她已停止履行当前职责，但Fiedler将继续担任公司高级顾问，直到她预计于2025年4月30日离职。

Jersey City, NJ-based pharmaceutical company Organon & Co. has reported a significant change in its executive team. Effective ...

周二，TD Cowen维持对Organon & Co. (NYSE:OGN)股票的"持有"评级，设定目标价为19.00美元。此举是在分析师覆盖从Steve Scala转移到Michael Nedelcovych之际。Organon最近分享了其业务运营的更新，其中包括对2025年的预测。

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on Organon (OGN – Research Report), with a price target of ...

Organon & Co.’s (NYSE:OGN) largest product, Nexplanon, is expected to generate $1 billion in revenue in 2025. The recent acquisition of Dermavant Sciences Ltd. in October 2024 enhanced the ...

The US Food and Drug Administration (FDA) gave approval to an implantable contraceptive called Implanon. The matchstick sized contraceptive is implanted beneath a woman's skin in the forearm and ...